July 12, 2017 10:31 AM EDT
Pharma

Pfiz­er’s da­ta min­ing hits pay dirt as FDA pan­el backs a come­back for My­lotarg

John Carroll

Editor & Founder

Sev­en years ago, My­lotarg was an em­bar­rass­ment for Pfiz­er and the FDA. Reg­u­la­tors forced it off the mar­ket in 2010, right af­ter Pfiz­er’s big Wyeth …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

Up­dat­ed: No­vo Nordisk sees growth slow­ing this year, plans Ca­griSe­ma fil­ing for 2026

Bris­tol My­ers, Ky­owa Kirin dis­close lay­offs

Eye­Point shares more mid-stage da­ta for ther­a­py try­ing to com­pete with Re­gen­eron's Eylea

A service from the Financial Times